Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma - Top-Institutions - MDSpire

Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma

  • By

  • Xiuqin An

  • Yanfang Gao

  • Shangyumeng Zhao

  • Wei He

  • Xinda Yang

  • Yujie Wu

  • Jihao Li

  • Runxi Yi

  • Yue Han

  • Mingxuan Li

  • Qiusheng Li

  • Ting Yang

  • June 17, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Hepatology
    • Immunotherapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Hepatology
    • Immunotherapy

  • #3

    Third Xiangya Hospital of Central South University
    Third Xiangya Hospital of Central South University

    Changsha, Hunan

    Key Differentiators

    • Oncology

  • #4

    Kyushu University
    Kyushu University

    Fukuoka, Fukuoka

    Key Differentiators

    • Oncology
    • Pathology

Original Source(s)

Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma

  • by Xiuqin An, Yanfang Gao, Shangyumeng Zhao, Wei He, Xinda Yang, Yujie Wu, Jihao Li, Runxi Yi, Yue Han, Mingxuan Li, Qiusheng Li, Ting Yang

  • June 17, 2026

Related Content

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system

2026 AACR Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min